Skip to main content
SLXNW logo

SLXNW · Silexion Therapeutics Corp · Documents

Track SLXNW — free
$0.00 +0.00 (+0.00%) At close · Nov 19
Market Cap
$974,292
Shares
649,528
Volume · Nov 19 300 Avg daily vol (3M) 39.06K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $11.91M 10-K filed Mar 17, 2026 Quarterly report FY2026 Q3 Net loss $2.53M 10-Q filed Nov 12, 2026 Latest results New SIL204 first patient dosed in pancreatic cancer trial 8-K filed Nov 16, 2026
2026
Nov 19
Current report 8-K
Nasdaq panel keeps listing with financing conditions and deadlines

A Nasdaq Hearings Panel granted Silexion continued listing, subject to conditions. The company must complete a $2.5 million private placement by December 4, 2026, and a public offering of at least $5 million by March 31, 2027.

Other events
4 source passages
On November 18, 2026, Silexion Therapeutics Corp. granting the Company’s request for continued listing on the Nasdaq Capital Market, subject to the conditions described below by December 4, 2026, complete its planned private placement financing for net proceeds of $2.5 million by March 31, 2027, complete a planned public offering of at least $5 million Open the document at this passage
Nov 16
Current report 8-K
SIL204 first patient dosed in pancreatic cancer trial

Silexion Therapeutics Corp dosed its first patient with SIL204 on September 30, 2026 in a Phase 2/3 pancreatic cancer trial at Tel Aviv Sourasky Medical Center. Cash and cash equivalents were $4.8 million.

Financial results
2 source passages
On July 29, 2026, Silexion initiated its Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer (“LAPC”) at Tel Aviv Sourasky Medical Center (“TASMC” or “Ichilov”), and on September 30, 2026, announced that the first patient worldwide had been dosed at TASMC. As of September 30, 2026, Silexion had cash and cash equivalents of $4.8 million, compared to $6.0 million as of December 31, 2025, and $2.2 million as of June 30, 2026. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
SIL204 trial doses first patient amid Nasdaq listing uncertainty

Silexion Therapeutics Corp dosed its first SIL204 Phase 2/3 patient in locally advanced pancreatic cancer, while awaiting a Nasdaq listing decision. The company reported an $8.8 million nine-month net loss and said cash would fund only several months.

Net loss $2.53M Diluted EPS $13.70 ▼ 98.0%
Read from the MD&A section
4 source passages
During the third quarter of 2026, we initiated and successfully dosed the first patient in our Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer subjects, at the Tel Aviv Sourasky Medical Center (Ichilov) in Tel Aviv, Israel. As of the date of the filing of this quarterly report, we have not yet received a decision from the Nasdaq hearings panel as to our request to remain listed on Nasdaq. Our net losses were $2.5 million and $8.8 million for the three-month and nine-month periods ended September 30, 2026, respectively, and $11.9 million for the year ended December 31, 2025. Based on our current business plan, we believe our current cash and cash equivalents, and anticipated cash flow from operations, will not be sufficient to meet our anticipated cash requirements for the next 12 months but rather only for several months, from the filing date of this quarterly report, under our current business plan. Open the document at this passage
Nov 12
Current report 8-K
Warrants adjusted after 1-for-24 reverse share split

Silexion Therapeutics Corp completed a 1-for-24 reverse share split effective after trading on November 10, 2026, leaving 21,495,833 authorized ordinary shares at $3.24 par value and adjusting warrants to 1/24 share each at $372,600.00 per share.

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Other events
5 source passages
In connection with its previously-announced 1-for-24 reverse share split of all of its issued and outstanding, and authorized but unissued, ordinary shares (the “Reverse Share Split”) described in Item 5.03 below, on November 11, 2026, Silexion Therapeutics Corp (the “Company”) issued a notice (the “Warrant Adjustment Notice”) to holders of its public warrants and private warrants to purchase the Company’s ordinary shares (the “Warrants”). The Reverse Share Split became effective after the close of business on November 10, 2026, and the Company’s ordinary shares began trading on a Reverse Share Split-adjusted basis on the Nasdaq Capital Market under the existing ticker symbol “SLXN” at the market open on November 11, 2026. As a result of that filing, the authorized share capital of the Company remains at $69,646,500, now consisting of 21,495,833 ordinary shares, and the par value of the ordinary shares has increased from $0.135 per share to $3.24 per share. the number of ordinary shares issuable upon exercise of each pre-Reverse Share Split Warrant to purchase one ordinary share decreased proportionately to the Reverse Share Split ratio, resulting in each such Warrant being exercisable for 1/24th of an ordinary share following the Reverse Share Split; and the exercise price of each post-Reverse Share Split Warrant to purchase one whole post-Reverse Share Split ordinary share was proportionately increased 24-fold (relative to a pre-Reverse Share Split Warrant to purchase one pre-Reverse Share Split ordinary share), to $372,600.00 per post-Reverse Share Split ordinary share. Open the document at this passage
Nov 9
Current report 8-K
1-for-24 reverse split begins trading November 11, 2026

Silexion Therapeutics Corp will conduct a 1-for-24 reverse share split after market close on November 10, 2026, with split-adjusted Nasdaq Capital Market trading beginning November 11, 2026 under ticker “SLXN”; par value will rise from $0.135 per share to $3.24 per share.

Other events
3 source passages
Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-24 reverse share split of its ordinary shares. The reverse share split will become effective after market close on November 10, 2026, and the Company’s ordinary shares will begin trading on a reverse split-adjusted basis on the Nasdaq Capital Market at market open on November 11, 2026, under the existing ticker symbol “SLXN.” The par value of the ordinary shares will be proportionately increased, from $0.135 per share to $3.24 per share, and no fractional shares will be issued. Open the document at this passage
Oct 28
Registration statement S-3
Resale registration of up to 8,813,531 shares by selling shareholders

Silexion Therapeutics registers resale of up to 8,813,531 ordinary shares by selling shareholders, including 1,414,266 note shares and 740,224 commercial shares. The shares stem from warrant inducement at $0.2603 per share, conversion of a Moringa Sponsor note and payment to LifeSci for services. The company receives no resale proceeds but may receive cash from warrant exercises.

Read from the first part of this long document
5 source passages
Up to 8,813,531 Ordinary Shares by the Selling Shareholders 1,414,266 ordinary shares (“Note Shares”) that we issued to a Selling Shareholder upon conversion of amounts owed by us to it 740,224 ordinary shares (“Commercial Shares”) at a reduced exercise price of $0.2603 per ordinary share We will not receive any proceeds from the resale of the ordinary shares by the Selling Shareholders. Open the document at this passage
Oct 26
Current report 8-K
Shareholders approve share capital increase and 1-for-24 reverse split

Silexion Therapeutics shareholders approved increasing authorized share capital by 500,000,000 ordinary shares, to 515,900,000, and a reverse split range of 1-for-15 to 1-for-25, with the Board setting 1-for-24.

Charter or bylaw amendment, or fiscal year change, Shareholder vote results
3 source passages
by creating 500,000,000 ordinary shares of a par value of US$0.135 each. to US$69,646,500 divided into 515,900,000 ordinary shares of a par value of US$0.135 each, within a range of 1-for-15 to 1-for-25, as determined by the Board, with the Board having determined a ratio of 1-for-24 Open the document at this passage
Oct 19
Proxy statement DEFA14A
Proxy statement

Silexion Therapeutics Corp (Nasdaq: SLXN) adjourned its October 19, 2026 extraordinary general meeting to October 26, 2026, to vote on increasing authorized share capital by 500,000,000 ordinary shares and authorizing a reverse share split of 1-for-15 to 1-for-25 to regain Nasdaq compliance.

Oct 5
Proxy statement DEF 14A
Proxy statement

Silexion Therapeutics Corp will ask shareholders on October 19, 2026 to approve adding 500,000,000 authorized ordinary shares and authorizing a reverse split from not less than 1-for-15 to not more than 1-for-25, both intended to support Nasdaq compliance.

Read from the first part of this long document
Sep 30
Current report 8-K
Regulation FD disclosure

Silexion Therapeutics Corp dosed the first patient worldwide in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, beginning an approximately 18-patient safety run-in followed by an approximately 166-patient randomized expansion.

Sep 29
Current report 8-K Events of Sep 28
Entered into a material agreement, Unregistered sale of equity, Other events

Silexion Therapeutics Corp expects approximately $0.84 million in gross proceeds from 3,216,928 warrant exercises at $0.2603 per share and will issue 3,216,928 Series F warrants and 3,216,928 Series G warrants to purchase up to 6,433,856 ordinary shares at $0.2603 per share.

Read from the first part of this long document
Sep 28
Current report 8-K
Regulation FD disclosure

Silexion Therapeutics Corp reported positive preclinical findings that SIL204 uses circulating lipoproteins for cellular uptake and dose-dependent mutant KRAS silencing; lipid depletion reduced knockdown (P < 0.001), while physiological lipid levels enabled uptake without artificial carriers.

Sep 25
Current report 8-K
Delisting notice or listing transfer

On September 25, 2026, Nasdaq notified Silexion Therapeutics Corp of a bid-price deficiency after 30 consecutive business days below $1.00 per share under Listing Rule 5550(a)(2). The hearings panel will consider Nasdaq Capital Market listing; shares and warrants continue trading.

Sep 25
Proxy statement PRE 14A
Proxy statement

Silexion Therapeutics Corp shareholders will vote on adding 500,000,000 authorized shares and authorizing a reverse split between 1-for-15 and 1-for-25 to restore Nasdaq compliance with $1.00 minimum bid price and $2.5 million shareholders’ equity requirements.

Read from the first part of this long document
Sep 25
Current report 8-K
Shareholder vote results

At its September 23, 2026 meeting, Silexion Therapeutics Corp shareholders rejected a 175,000,000-share authorized capital increase and authorization of a 1-for-15 reverse share split.

Aug 14
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Net loss $3.55M Diluted EPS $5.17 ▼ 88.0%
Aug 13
Current report 8-K
Other events AI summary on its way
Aug 3
Current report 8-K
Other events AI summary on its way
May 26
Current report 8-K
Other events AI summary on its way
May 15
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Net loss $2.73M Diluted EPS $0.85 ▼ 77.9%
Showing 1–50 of 146 documents
Key facts CIK 2022416 CUSIP G1281K148 13F (30d) 27 filings 21 filers Visit website Investor relations